Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
alleviate, appointed, Bandy, Bart, basic, Chair, classification, Committee, computation, compute, contingent, COSO, Dan, deficiency, deficit, detected, digital, disposal, disposed, document, doubt, Environment, expertise, fewer, formal, formalize, formalized, formula, Framework, Gladney, hand, Hickey, inaccurate, inconsequential, insignificant, insufficient, knowledge, lack, low, maintain, member, misstatement, ordinary, organizational, package, past, Paul, prevented, published, pursue, referenced, reimplement, release, remediation, role, satisfaction, serve, sought, Sponsoring, spreadsheet, Stankovich, Treadway, unexercised, warranty
Removed:
Apollo, capitalize, care, concluded, continuum, custom, decreased, depending, derivative, disclose, Endosurgery, extension, file, finalized, finalizing, flexibility, initially, introduce, invasive, iv, leverage, manufacture, minimally, October, offer, promote, reshapecareTM, reversed, seek, submit, synergistic, terminated, vi
Filing tables
Filing exhibits
Related press release
Associated RSLS transcripts
RSLS similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Thomas Stankovich, in his capacity as Chief Financial Officer of ReShape Lifesciences Inc., hereby certifies that, to the best of his knowledge:
1. | The Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 to which this Certification is attached as Exhibit 32.2 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and the results of operations of ReShape Lifesciences Inc. as of, and for, the periods covered by the Report. |
| ||
| By: | /s/ THOMAS STANKOVICH |
| | Thomas Stankovich |
| | Chief Financial Officer, Senior Vice President, Finance |
| | |
Date: August 19, 2022